Berlin, Germany, and Seattle, WA, U.S.A., December 19, 2012 - Epigenomics AG (Frankfurt
Prime Standard: ECX), the German-American cancer molecular diagnostics company, today
provided detailed results from a head-to-head comparative study between its blood-based
colorectal cancer (CRC) detection test Epi proColon® and fecal immunochemical testing (FIT)
for which it recently reported top-line results. This trial was designed to evaluate non-inferiority
of the blood based Epi proColon® assay performance in comparison to FIT.
The subjects included in the first arm of the study were average risk, asymptomatic screening
patients with no history (own or familial) of CRC. These patients were identified as CRC patients
in the context of screening colonoscopies performed from April-November 2012 across 70 sites
in the US.
As previously reported, in this study, Epi proColon® was able to detect 73 out of 103 cancer
cases, demonstrating an overall sensitivity of 71%. Clinical staging information of the disease
was available for 71 of the 103 cases.
Further analysis of the data shows that Epi proColon® was able to demonstrate 61% sensitivity
for 23 cases in stages 0 and 1 (FIT 61% sensitivity), 75% for 16 cases in stage 2 (FIT 75%
sensitivity), 70% for 20 cases in stage 3 (FIT 85% sensitivity) and 92% in 12 stage 4 cases (FIT
64% sensitivity). In the 32 cases of unknown clinical staging, the sensitivity was 69% (57%
sensitivity for FIT).
The correspondence of the blood and stool based test methods was 62%, whereby Epi proColon®
was able to identify 20 cases that could not be identified by FIT, while FIT identified 17 CRC
cases, which were not found through Epi proColon®.
The second arm of the study comprised 198 average risk individuals, which were prospectively
enrolled (i.e. before colonoscopy). Among these, 3 CRC cases were identified by colonoscopy.
Both, Epi proColon® and FIT were able to find 2 out of these three CRC cases. At the same time,
of the 24 advanced adenomas included in the second arm, neither method detected a significant
number of these. The adenoma detection for Epi proColon®, as shown in previous studies, was
low. Surprisingly, the finding was the same for FIT, although it was previously believed to be a
distinct advantage of this method.
Overall reported specificities for Epi proColon® and FIT were at 81% and 98% respectively.
While the point estimate of 81% specificity for Epi proColon® was still above the pre-defined
non-inferiority margin, this result was statistically non-significant. The difference in specificity is
less vital in the Company’s opinion, as patients will undergo a colonoscopy – the currently
recommended screening procedure – as a result of a positive test result. In addition to this it is
noteworthy that the Company’s CE marked version of the product, optimized for specificity and
launched in Europe earlier this year, has a specificity for CRC detection of 99%. This could open
additional possibilities to address the US market in the future.
Contact Epigenomics AG
Manager IR | PR
Tel +49 (0) 30 24345 368
Epigenomics (www.epigenomics.com) is a molecular diagnostics company developing and
commercializing a pipeline of proprietary products for cancer. The Company’s products enable
doctors to diagnose cancer earlier and more accurately, leading to improved outcomes for
patients. Epigenomics’ lead product, Epi proColon®, is a blood-based test for the early detection
of colorectal cancer, which is currently marketed in Europe and is in development for the U.S.A.
The Company’s technology and products have been validated through multiple partnerships with
leading global diagnostic companies including Abbott, QIAGEN, Sysmex, and Quest
Diagnostics. Epigenomics is an international company with operations in Europe and the U.S.A.
Epigenomics legal disclaimer
This communication expressly or implicitly contains certain forward-looking statements
concerning Epigenomics AG and its business. Such statements involve certain known and
unknown risks, uncertainties and other factors which could cause the actual results, financial
condition, performance or achievements of Epigenomics AG to be materially different from any
future results, performance or achievements expressed or implied by such forward-looking
statements. Epigenomics AG is providing this communication as of this date and does not
undertake to update any forward-looking statements contained herein as a result of new
information, future events or otherwise.
The information contained in this communication does not constitute nor imply an offer to sell or
transfer any product, and no product based on this technology is currently available for sale by
Epigenomics in the United States or Canada. The analytical and clinical performance
characteristics of any Epigenomics product based on this technology which may be sold at some
future time in the U.S. have not been established.